Le Lézard

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs

Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief ...
The Manila Times

Jackery Expands ‘Essential Home Backup Solution’ to the Yard, Launches Solar Gazebo and Autonomous Solar Mars Bot at CES 2026

Marking its 10th anniversary of the debut of Jackery’s Portable Power Station, Jackery is extending its home energy solutions ...

How McCrory probe derailed a program to help Hartford businesses

The program was to help minority-owned businesses in Hartford’s north end with training and grants up to $15,000. Then ...
Le Lézard

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase II ...